Rectal Cancer - Pipeline Review, H2 2016

Date: August 17, 2016
Pages: 107
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R9D3B77F474EN
Leaflet:

Download PDF Leaflet

Rectal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Rectal Cancer - Pipeline Review, H2 2016’, provides an overview of the Rectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
  • The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Rectal Cancer
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Rectal Cancer Overview
Therapeutics Development
Pipeline Products for Rectal Cancer - Overview
Rectal Cancer - Therapeutics under Development by Companies
Rectal Cancer - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Rectal Cancer - Products under Development by Companies
Rectal Cancer - Companies Involved in Therapeutics Development
AbbVie Inc
Advaxis, Inc.
Cerulean Pharma, Inc.
Hanwha Chemical Corporation
Karyopharm Therapeutics, Inc.
Regeneron Pharmaceuticals Inc
Taiwan Liposome Company, Ltd.
Rectal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
axalimogene filolisbac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HD-204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nimotuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLC-388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rectal Cancer - Dormant Projects
Rectal Cancer - Product Development Milestones
Featured News & Press Releases
Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Rectal Cancer, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Rectal Cancer - Pipeline by AbbVie Inc, H2 2016
Rectal Cancer - Pipeline by Advaxis, Inc., H2 2016
Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H2 2016
Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Rectal Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Rectal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Rectal Cancer - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Rectal Cancer, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Rectal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 112 pages
Colorectal Cancer - Pipeline Review, 2015 US$ 3,200.00 Oct, 2015 · 258 pages
Colon Cancer - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 670 pages
Endometrial Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 412 pages
Kidney Cancer - Pipeline Review, H1 2015 US$ 1,600.00 Jun, 2015 · 847 pages

Ask Your Question

Rectal Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: